Company Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth.
It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide.
Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Mar 20, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 167 |
| CEO | John P. Butler MBA |
Contact Details
Address: 245 First Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617-871-2098 |
| Website | akebia.com |
Stock Details
| Ticker Symbol | AKBA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001517022 |
| CUSIP Number | 00972D105 |
| ISIN Number | US00972D1054 |
| Employer ID | 20-8756903 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John P. Butler MBA | Chief Executive Officer, President, Interim Principal Financial Officer and Director |
| Michel Dahan | Senior Vice President and Chief Operating Officer |
| Nicole R. Hadas J.D. | Senior Vice President, Chief Legal Officer and Secretary |
| Dr. Steven Keith Burke M.D. | Senior Vice President of Research and Development and Chief Medical Officer |
| Richard C. Malabre | Chief Accounting Officer |
| Kimberly Garko | Senior Vice President and Chief Technical Officer |
| Tracey Vetterick | Vice President of Portfolio Strategy and Corporate Administration |
| Mercedes Carrasco | Director of Corporate Communications |
| Meredith Bowman | Senior Vice President and Chief People Officer |
| Carolyn Rucci | Senior Vice President of Legal and General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | 144 | Filing |
| May 13, 2024 | 144 | Filing |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 23, 2024 | 8-K | Current Report |
| Apr 16, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 8-K | Current Report |